Dr. David A. Neumann II, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 673
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
OK license 28977 -
Internal Medicine Physician
OK license 28977
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Integris Baptist Medical Center, Inc Oklahoma City, OK
- Integris Southwest Medical Center Oklahoma City, OK
- Oklahoma Heart Hospital, LLC Oklahoma City, OK
- Integris Canadian Valley Hospital Yukon, OK
- Integris Health Enid Hospital Enid, OK
Medical groups
- Digestive Disease Specialists Inc (18 clinicians)
- Integris Bass Baptist Health Center (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 673
- Services billed
- 42,278
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, vedolizumab, 1 mg | 14,400 | 13 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 261 | 255 |
| Biopsy of large bowel using a flexible endoscope | 189 | 189 |
| Established patient office or other outpatient visit, 30-39 minutes | 179 | 135 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 178 | 168 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 107 | 76 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 84 | 84 |
| Established patient office or other outpatient visit, 20-29 minutes | 80 | 69 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | 17 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 52 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Oklahoma City, OK | 618 |
| Pantoprazole Sodium Other prescribers in Oklahoma City, OK | 438 |
| Famotidine Other prescribers in Oklahoma City, OK | 264 |
| Mesalamine Other prescribers in Oklahoma City, OK | 144 |
| Ursodiol Other prescribers in Oklahoma City, OK | 134 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Oklahoma City, OK | 116 |
| Creon (lipase/protease/amylase) Other prescribers in Oklahoma City, OK | 103 |
| Metoclopramide Hcl Other prescribers in Oklahoma City, OK | 81 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Oklahoma City, OK | 80 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Oklahoma City, OK | 76 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 114 payments worth $2,042 in total to this clinician.
| AbbVie Inc. | $693 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $435 |
| Lilly USA, LLC | $179 |
| Ipsen Biopharmaceuticals, Inc | $105 |
| Gilead Sciences, Inc. | $82.27 |
| Enterra Medical, Inc. | $80.00 |
| Medtronic, Inc. | $76.50 |
| Genzyme Corporation | $74.49 |
| Food and Beverage | $2,042 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.